688029 南微医学
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,012,44615.30%2,411,4681,980,1431,946,7241,326,406
减:营业总成本1,467,68513.49%1,854,3141,636,2101,621,5761,079,376
    其中:营业成本651,1763.77%855,982773,247697,290454,191
               财务费用(32,709)-48.20%(77,832)(60,670)20,84515,536
               资产减值损失(18,459)24.16%(34,641)(22,045)(22,508)(10,074)
公允价值变动收益(6)-100.28%16132----
投资收益15,372-18.99%27,82543,09965,38849,233
    其中:对联营企业和合营企业的投资收益9,86624.23%8,39011,24016,5409,967
营业利润540,08217.97%554,669364,162367,185282,229
利润总额542,24719.08%564,910367,872377,345300,989
减:所得税费用78,21429.74%70,20935,02747,99334,852
净利润464,03317.45%494,701332,845329,352266,136
减:非控股权益12,93951.33%8,7762,2544,6015,377
股东净利润451,09416.70%485,924330,590324,751260,760

市场价值指针
每股收益 (元) *2.41016.99%2.5901.7701.7401.956
每股派息 (元) *0.500--1.0000.5500.7500.600
每股净资产 (元) *19.8626.26%19.22817.17022.00719.581
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容